BEIJING SUNBIO BIOTECH CO., LTD. Patent applications |
Patent application number | Title | Published |
20140342994 | Fusion Protein Comprising Circularly Permuted Form Of Trail/Apo2L, Coding Gene And Use Thereof - Provided is a fusion protein comprising circularly permuted form of TRAIL, and the fusion protein contains circularly permuted form of TRAIL and oligopeptides located at the N-terminus and/or C-terminus of the permuted form. The oligopeptides contain a repeating sequence consisting of 3-10 histidines. The components of the circularly permuted form of TRAIL from N-terminus to C-terminus are: (a) amino acids 135-281 of TRAIL, (b) a linker, and (c) amino acids 121-135 of TRAIL or amino acids 114-135 of TRAIL or amino acids 95-135 of TRAIL or any fragments of amino acids 95-135 of TRAIL containing amino acids 121-135 of TRAIL. Also provided is a method for treating cancer by using the fusion protein. | 11-20-2014 |
20140206025 | Use Of Detection Of Aspartate Transaminase And Lactate Dehydrogenase In Early Evaluation Of Clinical Efficacy Of Antitumor Intervention Measure - The present invention relates to a method for early evaluation of clinical efficacy of antitumor intervention measure, comprising evaluating the efficacy of the antitumor intervention measure by assaying whether the content of a tumor-damaging biomarker(s) in the blood of a patient having tumor rises as compared to the baseline level before treatment within a time window after the patients receives at least one antitumor intervention measure. In preferable embodiments, the tumor-damaging biomarker(s) is selected from a group consisting of Alanine Aminotransferase (ALT), Aspartate Transaminase (AST), Lactate Dehydrogenase (LDH); said tumor is multiple myeloma; said antitumor intervention measure is the administration of CPT alone or the administration of CPT in combination with thalidomide. | 07-24-2014 |
20100158930 | HPV ANTIGEN FUSION PROTEIN VACCINE COMPOSITIONS AND USES THEREOF - The present invention provides a fusion protein comprising an immunostimulatory polypeptide and a mutant E7 protein of a human papilloma virus. The present invention also provides a gene encoding the fusion protein, expression vectors containing the gene, a pharmaceutical composition comprising the fusion protein, a method for treating or preventing a human papilloma virus related disease by using the fusion protein and uses of the fusion protein in the preparation of a medicament for the treatment or prevention of the human papilloma virus related disease. | 06-24-2010 |